{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:50:00Z","timestamp":1774684200005,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":189,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008246","name":"Tufts University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002544"],"award-info":[{"award-number":["UL1TR002544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100833","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T17:44:10Z","timestamp":1720547050000},"page":"100833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-8455","authenticated-orcid":false,"given":"Xiao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana V.","family":"Salei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctarc.2024.100833_bib0001","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2024.100833_bib0002","unstructured":"Society AC. Cancer Facts & Figures 2018 [Available from: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2018\/cancer-facts-and-figures-2018.pdf."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100833_bib0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100833_bib0004","doi-asserted-by":"crossref","first-page":"354","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review","volume":"11","author":"Olivares-Hernandez","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"10212","key":"10.1016\/j.ctarc.2024.100833_bib0005","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ctarc.2024.100833_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100833_bib0007","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, Version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"39","key":"10.1016\/j.ctarc.2024.100833_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy","author":"Nazha","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8","key":"10.1016\/j.ctarc.2024.100833_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjmed.2022.03.042","article-title":"Disparities in representation of women, older adults, and racial\/ethnic minorities in immune checkpoint inhibitor trials","volume":"135","author":"Riaz","year":"2022","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100833_bib0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.36401\/JIPO-21-6","article-title":"Immunotherapy in special and rare situations: a brief review","volume":"4","author":"Srinivas","year":"2021","journal-title":"J. ImmunOther Precis. Oncol."},{"issue":"13","key":"10.1016\/j.ctarc.2024.100833_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137068","article-title":"Immunotherapy in NSCLC patients with brain metastases","volume":"23","author":"Buriolla","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2024.100833_bib0012","first-page":"1","article-title":"Immune-based cancer treatment: addressing disparities in access and outcomes","volume":"41","author":"Osarogiagbon","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.ctarc.2024.100833_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy","volume":"39","author":"Nazha","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100833_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2020.6362","article-title":"Proportion of never smokers among men and women with lung cancer in 7 US states","volume":"7","author":"Siegel","year":"2021","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100833_bib0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1513\/AnnalsATS.201907-556CME","article-title":"Disparities in lung cancer screening: a review","volume":"17","author":"Haddad","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100833_bib0017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jtho.2021.07.031","article-title":"Screening for lung cancer in individuals who never smoked: an international association for the study of lung cancer early detection and screening committee report","volume":"17","author":"Kerpel-Fronius","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100833_bib0018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ctarc.2024.100833_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100833_bib0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/1759-7714.12966","article-title":"Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation","volume":"10","author":"Zehentmayr","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100833_bib0023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0024","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100833_bib0025","unstructured":"Common terminology criteria for adverse events (CTCAE) Version 5.0. Accessed on March 29th, 2024. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5\u00d77.pdf."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100833_bib0026","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/oncolo\/oyad125","article-title":"Neoadjuvant versus adjuvant systemic therapy for early-stage non-small cell lung cancer: the changing landscape due to immunotherapy","volume":"28","author":"John","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2024.100833_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.877594","article-title":"Immunotherapy in non-small cell lung cancer: past, present, and future directions","volume":"12","author":"Punekar","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2024.100833_bib0028","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/EDBK_179850","article-title":"Caring for the older population with advanced lung cancer","volume":"37","author":"Presley","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100833_bib0030","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2024.100833_bib0031","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.2147\/IJGM.S342009","article-title":"Brain metastasis in patients with small cell lung cancer","volume":"14","author":"Li","year":"2021","journal-title":"Int. J. Gen. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100833_bib0032","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.32817","article-title":"Use of immunotherapy and surgery for stage IV melanoma","volume":"126","author":"Molina","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100833_bib0033","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12916-020-01753-0","article-title":"Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis","volume":"18","author":"Norris","year":"2020","journal-title":"BMC. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100833_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6888","article-title":"Factors influencing receipt and time to treatment of immunotherapy relative to chemotherapy in stage III and stage IV melanoma","volume":"13","author":"Dhaliwal","year":"2024","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CJI.0000000000000253","article-title":"Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States","volume":"42","author":"Verma","year":"2019","journal-title":"J. ImmunOther"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100833_bib0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5306\/wjco.v12.i2.103","article-title":"Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses","volume":"12","author":"Peravali","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2024.100833_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e15148","article-title":"Racial differences in development of immune-related adverse events","volume":"38","author":"Bhandari","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100833_bib0038","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.6004\/jnccn.2023.7064","article-title":"Similar efficacy observed for first-line immunotherapy in racial\/ethnic minority patients with metastatic NSCLC","volume":"21","author":"Lee","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2024.100833_bib0039","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100833_bib0040","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100833_bib0041","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/CJI.0000000000000440","article-title":"A single center retrospective study of the impact of COVID-19 infection on immune-related adverse events in cancer patients receiving immune checkpoint inhibitors","volume":"45","author":"Guo","year":"2022","journal-title":"J. ImmunOther."},{"issue":"28","key":"10.1016\/j.ctarc.2024.100833_bib0042","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100833_bib0043","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2024.100833_bib0044","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2024.100833_bib0045","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100833_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100833_bib0047","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ni.3147","article-title":"The impact of host genetic variation on infection with HIV-1","volume":"16","author":"McLaren","year":"2015","journal-title":"Nat. Immunol."},{"issue":"47","key":"10.1016\/j.ctarc.2024.100833_bib0048","doi-asserted-by":"crossref","first-page":"14658","DOI":"10.1073\/pnas.1514867112","article-title":"Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load","volume":"112","author":"McLaren","year":"2015","journal-title":"Proc. Natl Acad. Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100833_bib0049","article-title":"Host genetic impact on infectious diseases among different ethnic groups","volume":"4","author":"Naidoo","year":"2023","journal-title":"Adv. Genet. (Hoboken)"},{"issue":"11","key":"10.1016\/j.ctarc.2024.100833_bib0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","article-title":"Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas","volume":"64","author":"Lin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ctarc.2024.100833_bib0051","article-title":"Screening, diagnosis, and initial care of asian and white patients with lung cancer","author":"Hu","year":"2023","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ctarc.2024.100833_bib0052","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1002\/ijc.32717","article-title":"Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies","volume":"146","author":"Qian","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"11_suppl","key":"10.1016\/j.ctarc.2024.100833_bib53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/OP.2023.19.11_suppl.156","article-title":"Real-world data on immune-checkpoint inihibitors use and immune-related advserse events in lung cancer","volume":"19","author":"Hu","year":"2023","journal-title":"JCO Oncol. Pract."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T06:10:38Z","timestamp":1728454238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":53,"alternative-id":["S2468294224000455"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100833","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100833"}}